On Thursday, AbbVie Inc. (NYSE:ABBV)’s shares climbed, after AbbVie, declared that 29 abstracts from its ongoing hepatitis C clinical development program have been accepted for presentation during The International Liver CongressTM (ILC) 2015 in Vienna, Austria from April 22-26. Data being presented comprise sub-analyses of the recently approved VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets), Phase 3b studies, counting a head-to-head comparison of AbbVie’s three direct-acting antiviral treatment with telaprevir-based therapy and Phase 2/3 studies investigating AbbVie’s combination treatment in genotype 1 (GT1) and genotype 4 (GT4). Additionally, data from Phase 1 studies of ABT-493 and ABT-530 will be presented.
AbbVie’s ongoing HCV pipeline development program focuses on investigating a pan-genotypic, ribavirin (RBV)-free, once-daily treatment that may also allow for treatment durations of as little as eight weeks. Preliminary results from a Phase 2b study (n=79) of ABT-493 and ABT-530 in non-cirrhotic GT1 patients receiving the RBV-free recommended regimen for 12 weeks demonstrated a sustained virologic response rate at four weeks post treatment (SVR4) of 99 percent (n=78/79). These results, declared for the first time recently, comprised of both GT1a and GT1b, treatment-naïve and pegylated-interferon and RBV preceding null responders. Patients across both study arms were randomized to receive ABT-493 (200mg) and either 120mg or 40mg of ABT-530. To date, the most ordinary (>5 percent) adverse reactions were fatigue, headache, nausea, diarrhea and anxiety. Data from these Phase 2b studies of ABT-493 and ABT-530 will not be presented at ILC 2015, and will be released at future medical congresses.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The companys products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s shares jumped during the last trading session on Thursday, after Inovio Pharmaceuticals, declared that it was recognized with a prestigious industry award at the World Vaccine Congress being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine advancements and achievements of therapeutic and preventive vaccine developers across the worldwide industry as judged by a panel of global biotech industry stakeholders.
Inovio was given accolades by its industry peers for “Best Therapeutic Vaccine” for its DNA-based immunotherapy, VGX-3100, which was designed to treat HPV-associated precancers and cancers. In a large, controlled phase II efficacy trial Inovio stated top line data demonstrating regression of disease and clearance of the underlying cause of the condition — the HPV virus. Inovio anticipates to publish the complete data set in a peer-reviewed journal this year, is advancing this product into a phase III trial early next year, and has expanded studies of this immunotherapy to comprise cervical and head and neck cancer.
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
At the end of Thursday’s trade, CNO Financial Group, Inc. (NYSE:CNO)’s shares climbed, as Bankers Life was recently recognized for excellence in its field and home office training programs by Training magazine’s Training Top 125.
Bankers Life, which focuses on the life and health insurance needs of Americans who are near or in retirement, earned the No. 51 spot on the Training Top 125 list for 2015.
This marks the fourth successive year that Bankers Life has secured a spot in the annual rankings, which recognize organizations for providing world class employer-sponsored workforce training and development programs.
Bankers Life, recognized for its outstanding field and home office training initiatives, provides multi-faceted lifelong learning tools for all levels of its field force compriseing of over 4,800 agents and managers at more than 300 office locations across the US. Learning and development opportunities comprise workshops, live best practice forums, and web-based and on-demand training.
Now in its 15th year, the Training Top 125 ranking is determined by assessing a range of factors, counting financial investment in employee development, the scope of development programs, and how closely such development efforts are linked to business aims and objectives.
CNO Financial Group, Inc., through its auxiliaries, develops, markets, and administers health insurance, annuity, individual life insurance, and other insurance products for senior and middle-revenue markets in the United States.
Skyworks Solutions Inc. (NASDAQ:SWKS), ended its Thursday’s trading session in Green, as an innovator of high performance analog semiconductors connecting people, places and things, will conduct a conference call with analysts to talk about its second quarter fiscal 2015 results and business outlook on April 30, 2015 at 5:00 p.m. Eastern time.
After the close of the market on April 30, and preceding to the conference call, Skyworks will issue a copy of the earnings press release via Business Wire.
To listen to the conference call via the Internet, please visit the investor relations section of Skyworks’ website. To listen to the conference call via telephone, please call 800-230-1092 (domestic) or 612-288-0337 (international), confirmation code: 357740.
Skyworks Solutions, Inc., together with its auxiliaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
